US20170119888A1 - Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods - Google Patents
Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods Download PDFInfo
- Publication number
- US20170119888A1 US20170119888A1 US15/408,748 US201715408748A US2017119888A1 US 20170119888 A1 US20170119888 A1 US 20170119888A1 US 201715408748 A US201715408748 A US 201715408748A US 2017119888 A1 US2017119888 A1 US 2017119888A1
- Authority
- US
- United States
- Prior art keywords
- acceptable salt
- physiologically
- solvent
- bak
- cationic preservative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/65—Metal complexes of amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
Definitions
- the invention relates generally to preserved compositions containing hyaluronic acid (HA) or a physiologically-acceptable salt thereof, and more particularly, to HA compositions preserved with cationic preservatives such as benzalkonium chloride (BAK).
- HA hyaluronic acid
- BAK benzalkonium chloride
- Hyaluronic acid is a mucopolysaccharide found in various physiological fluids, including vitreous humor.
- the ability of HA to retain water has made it popular as a lubricant or wetting agent in various health care and pharmaceutical compositions, such as ophthalmic, otic, and nasal compositions.
- compositions administered to an individual typically include an antimicrobial preservative.
- an antimicrobial preservative is benzalkonium chloride (BAK).
- BAK benzalkonium chloride
- HA and cationic preservatives, such as BAK are incompatible, resulting in their conjugation and precipitation, thereby reducing both the lubricating and preservative properties of the composition. While the loss of such properties may sometimes be overcome by increasing the concentration of one or both compounds, BAK is believed to cause corneal disorders at high concentrations.
- the invention provides a composition containing hyaluronic acid (HA) or a pharmaceutically-acceptable salt thereof, preserved with a cationic preservative.
- HA hyaluronic acid
- pharmaceutically-acceptable salt is sodium hyaluronate.
- cationic preservative includes benzalkonium chloride (BAK).
- a first aspect of the invention provides a method for preparing a preserved hyaluronic acid composition, the method comprising: dissolving a cationic preservative in a first quantity of a solvent; dissolving a quantity of hyaluronic acid (HA) or physiologically-acceptable salt thereof in a second quantity of the solvent; and adding the dissolved HA or physiologically-acceptable salt thereof to the dissolved cationic preservative, wherein precipitation of the cationic preservative and the HA or physiologically-acceptable salt thereof is substantially prevented by dissolving each in the first and second quantities of solvent before they are combined.
- HA hyaluronic acid
- a second aspect of the invention provides a method for preparing a preserved hyaluronic acid composition, the method comprising: dissolving a cationic preservative in a first quantity of a solvent; dissolving a quantity of hyaluronic acid (HA) or physiologically-acceptable salt thereof in a second quantity of the solvent; dissolving a quantity of an anionic cellulose derivative in a third quantity of the solvent; adding the dissolved HA or physiologically-acceptable salt thereof to the dissolved cationic preservative; and adding the dissolved anionic cellulose derivative to at least one of the following: the dissolved HA or physiologically-acceptable salt thereof, the dissolved cationic preservative, and the combined dissolved HA or physiologically-acceptable salt thereof and cationic preservative, wherein precipitation of the cationic preservative and the HA or physiologically-acceptable salt thereof is substantially prevented by dissolving each in the first and second quantities of solvent before they are combined.
- a third aspect of the invention provides a preserved aqueous composition
- a preserved aqueous composition comprising: a solvent; hyaluronic acid (HA) or a physiologically-acceptable salt thereof; and an effective amount of a cationic preservative including benzalkonium chloride (BAK) having the formula [C 6 H 5 CH 2 N(CH 3 )R]Cl, wherein R is an alkyl group having at least one of: between eight and 10 and between 14 and 18 carbon atoms, wherein the composition is substantially free of precipitants of the cationic preservative and the HA or physiologically-acceptable salt thereof.
- BAK benzalkonium chloride
- the invention provides a hyaluronic acid (HA) composition preserved with a cationic preservative such as benzalkonium chloride (BAK) and methods for its preparation.
- HA hyaluronic acid
- BAK benzalkonium chloride
- the predilution of HA and BAK in particular ratios of solvent yields a combined composition exhibiting little or no HA-BAK conjugation and precipitation.
- the HA or a pharmaceutically-acceptable salt thereof is dissolved in a quantity of solvent equal to about 1/3 the total desired volume of the final composition while the cationic preservative, such as BAK, is dissolved in a quantity of solvent equal to about 2/3 the total desired volume of the final composition. That is, the quantity of solvent used to dissolve the BAK is approximately twice that used to dissolve the HA.
- HA or a pharmaceutically-acceptable salt thereof such as sodium hyaluronate
- BAK and/or another cationic preservative in about 200 mL of solvent.
- compositions according to the invention may be prepared using any number of solvents, subject to their suitability for administration.
- the solvent is typically aqueous, comprising water alone or in combination with one or more other solvents.
- Suitable solvents for ophthalmic, nasal, and otic compositions include, for example, glycerin, polyethylene glycol (PEG), and propylene glycol.
- BAK has the formula: [C 6 H 5 CH 2 N(CH 3 )R]Cl, wherein R is an alkyl group having between eight and 18 carbon atoms.
- compositions according to the invention optionally contain between about 0.001% and about 0.02% BAK or, optionally, between about 0.002% and about 0.01% BAK, or, optionally, between about 0.003% and about 0.005% BAK, or, optionally about 0.005% BAK.
- concentrations of BAK may be obtained by diluting commercially-available BAK solutions, which are available in any number of concentrations. Most commercially-available BAK solutions contain between about 5% and about 50% BAK. In certain embodiments, the BAK solutions contain between about 10% and about 30% BAK, or, optionally, between about 15% and about 19% BAK, or, optionally, about 17% BAK.
- the HA has a molecular weight between about 500,000 daltons and about 4,000,000 daltons, or, optionally, between about 1,000,000 daltons and about 2,000,000 daltons, or, optionally, between about 1,200,000 daltons and about 1,800,000 daltons.
- Certain embodiments of the present invention contain between about 0.1% and about 0.5% HA, or, optionally, between about 0.2% and about 0.4% HA, or, optionally, about 0.2% HA. More detailed discussions of HA can be found in U.S. Patent Publication 20060094643; and U.S. Pat. Nos.
- the composition may optionally be filtered to remove any minor HA-BAK precipitants or other agents affecting the composition's clarity.
- the compositions of the invention has a transmittance between about 93% and about 98% at 440 nm before filtration and a transmittance between about 95% and about 100% at 440 nm after filtration. Any method of filtration suitable for use with pharmaceutical compositions may be employed in practicing the invention.
- Alternative cationic preservatives useful either alone or in combination with BAK include, but are not limited to, poly[dimethylimino-w-butene-1,4-diyl] chloride, alpha-[4-tris(2-hydroxyethyl)ammonium]-dichloride (Polyquaternium 1®), poly (oxyethyl (dimethyliminio)ethylene dmethyliminio) ethylene dichloride (WSCP®), benzalkonium halides other than BAK, salts of alexidine, alexidine-free base, salts of chlorhexidine, hexetidine, alkylamines, alkyl di- and tri-amine, Octenidine (N,N[prime]-(1,10-Decanediyldi-1-(4H)-pyridinyl-4-ylidenebis-[1-octanamine] dihydrochloride, cetylpyridinium chloride, cetylpyridinium salts
- compositions according to the invention may contain additional components, such as those commonly found in ophthalmic, nasal, and otic compositions.
- additional components include, for example, cellulose derivatives, medicaments (e.g., antibacterials, antifungals, etc.), and buffers (e.g., phosphate buffers, borate buffers, citrate buffers, etc.).
- buffers e.g., phosphate buffers, borate buffers, citrate buffers, etc.
- Other components may be included in compositions according to the invention, depending upon how and where the composition is to be administered. A more detailed discussion of such components can be found in US Patent Publication 2007036829, herein incorporated by reference in its entirety.
- anionic cellulose derivatives are defined as carboxyalkyl celluloses and hydroxyalkyl celluloses where the alkyl group includes between 1 and 3 carbon atoms.
- the anionic cellulose derivative is selected from the group consisting of, carboxymethylethylcellulose, ethyl carboxyethyl cellulose, carboxymethylhydroxyethylcelluloses, hydroxypropylmethylcelluloses, metal salts of carboxymethyl cellulose (such as sodium carboxymethyl cellulose) and mixtures thereof.
- the anionic cellulose derivative is a metal salt of carboxymethyl cellulose.
- one or more anionic cellulose derivatives may be dissolved in the fraction containing the cationic preservative, which is then combined with the fraction containing the HA or pharmaceutically-acceptable salt thereof.
- the anionic cellulose derivatives employed have molecular weight range of from about 70,000 daltons to about 700,000 daltons.
- a third fraction of solvent may be separately employed to dissolve the CMC, which is then combined with the dissolved HA, the dissolved cationic preservative, or the combined HA (or pharmaceutically-acceptable salt) and cationic preservative fractions.
- the solvent fractions are optionally in a ratio of about 1:1:1. For example, if one were to prepare 300 mL of a composition according to the invention, about 100 mL of solvent would be used to separately dissolve the HA (or pharmaceutically-acceptable salt), the cationic preservative, and the CMC.
- compositions according to the invention will be described with reference to the following examples.
- Example 1 yielded 300 mL of an aqueous composition comprising: 0.133% sodium hyaluronate, 0.0033% BAK, and 0.33% CMC.
- Example 2 yielded 300 mL of an aqueous composition comprising: 0.2% sodium hyaluronate, 0.005% BAK, and 0.5% CMC.
- the filtered solution had a transmittance of about 100%.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a composition containing hyaluronic acid (HA) or a pharmaceutically-acceptable salt thereof preserved with a cationic preservative and related methods. In one embodiment, the pharmaceutically-acceptable salt is sodium hyaluronate. In another embodiment, the cationic preservative includes benzalkonium chloride (BAK).
Description
- The present application is a continuation of and claims the benefit of the earlier filing date of U.S. patent application Ser. No. 14/086,548 filed Nov. 21, 2013 which is a continuation of and claims the benefit of the earlier filing date of U.S. patent application Ser. No. 11/803,873, filed May 16, 2007, which is now U.S. Pat. No. 8,609,634, Issued Dec. 17, 2013, the entirety of which application is hereby incorporated herein by reference as if fully set forth herein.
- The invention relates generally to preserved compositions containing hyaluronic acid (HA) or a physiologically-acceptable salt thereof, and more particularly, to HA compositions preserved with cationic preservatives such as benzalkonium chloride (BAK).
- Hyaluronic acid (HA) is a mucopolysaccharide found in various physiological fluids, including vitreous humor. The ability of HA to retain water has made it popular as a lubricant or wetting agent in various health care and pharmaceutical compositions, such as ophthalmic, otic, and nasal compositions.
- To reduce the likelihood of infection due to microbial growth within compositions administered to an individual, such compositions typically include an antimicrobial preservative. One particularly effective antimicrobial preservative is benzalkonium chloride (BAK). However, it has been observed that HA and cationic preservatives, such as BAK, are incompatible, resulting in their conjugation and precipitation, thereby reducing both the lubricating and preservative properties of the composition. While the loss of such properties may sometimes be overcome by increasing the concentration of one or both compounds, BAK is believed to cause corneal disorders at high concentrations.
- Similar precipitation has been noted between BAK and latanoprost. U.S. Patent Application Publication No. 20060069162 to Asada et al. discloses several methods for avoiding such precipitation. These include the addition of a surfactant, the use of a particular species of BAK (i.e., [C6H5CH2N(CH3)R]Cl, wherein R is alkyl having 12 carbon atoms (BAK-C12)), and/or the addition of a nonionic tonicity agent. Such methods are unacceptable, however, as they require the inclusion of additional components to the composition, which increases complexity, expense, and the likelihood of adverse interactions, and/or the restriction of one component to a purified, and more expensive, species.
- To this extent, a need exists for preserved compositions containing HA that do not suffer from the defects known in the art.
- The invention provides a composition containing hyaluronic acid (HA) or a pharmaceutically-acceptable salt thereof, preserved with a cationic preservative. In one embodiment, the pharmaceutically-acceptable salt is sodium hyaluronate. In another embodiment, the cationic preservative includes benzalkonium chloride (BAK).
- A first aspect of the invention provides a method for preparing a preserved hyaluronic acid composition, the method comprising: dissolving a cationic preservative in a first quantity of a solvent; dissolving a quantity of hyaluronic acid (HA) or physiologically-acceptable salt thereof in a second quantity of the solvent; and adding the dissolved HA or physiologically-acceptable salt thereof to the dissolved cationic preservative, wherein precipitation of the cationic preservative and the HA or physiologically-acceptable salt thereof is substantially prevented by dissolving each in the first and second quantities of solvent before they are combined.
- A second aspect of the invention provides a method for preparing a preserved hyaluronic acid composition, the method comprising: dissolving a cationic preservative in a first quantity of a solvent; dissolving a quantity of hyaluronic acid (HA) or physiologically-acceptable salt thereof in a second quantity of the solvent; dissolving a quantity of an anionic cellulose derivative in a third quantity of the solvent; adding the dissolved HA or physiologically-acceptable salt thereof to the dissolved cationic preservative; and adding the dissolved anionic cellulose derivative to at least one of the following: the dissolved HA or physiologically-acceptable salt thereof, the dissolved cationic preservative, and the combined dissolved HA or physiologically-acceptable salt thereof and cationic preservative, wherein precipitation of the cationic preservative and the HA or physiologically-acceptable salt thereof is substantially prevented by dissolving each in the first and second quantities of solvent before they are combined.
- A third aspect of the invention provides a preserved aqueous composition comprising: a solvent; hyaluronic acid (HA) or a physiologically-acceptable salt thereof; and an effective amount of a cationic preservative including benzalkonium chloride (BAK) having the formula [C6H5CH2N(CH3)R]Cl, wherein R is an alkyl group having at least one of: between eight and 10 and between 14 and 18 carbon atoms, wherein the composition is substantially free of precipitants of the cationic preservative and the HA or physiologically-acceptable salt thereof.
- The illustrative aspects of the present invention are designed to solve the problems herein described and other problems not discussed, which are discoverable by a skilled artisan.
- As indicated above, the invention provides a hyaluronic acid (HA) composition preserved with a cationic preservative such as benzalkonium chloride (BAK) and methods for its preparation.
- The term “comprising” (and its grammatical variations) as used herein is used in the inclusive sense of “having” or “including” and not in the exclusive sense of “consisting only of.” The terms “a” and “the” as used herein are understood to encompass the plural as well as the singular.
- Where patents or patent applications are incorporated by reference herein and inconsistencies exist between the incorporated documents and the present disclosure, the present disclosure will prevail.
- Surprisingly, it has been found that the conjugation and/or precipitation of HA and cationic preservatives such as BAK may be avoided or minimized by preparing separate HA and BAK solutions which are then combined.
- More specifically, while the separate predilution of HA and BAK itself yields a combined composition exhibiting reduced HA-BAK conjugation and precipitation, the predilution of HA and BAK in particular ratios of solvent yields a combined composition exhibiting little or no HA-BAK conjugation and precipitation. In one embodiment, the HA or a pharmaceutically-acceptable salt thereof is dissolved in a quantity of solvent equal to about 1/3 the total desired volume of the final composition while the cationic preservative, such as BAK, is dissolved in a quantity of solvent equal to about 2/3 the total desired volume of the final composition. That is, the quantity of solvent used to dissolve the BAK is approximately twice that used to dissolve the HA.
- For example, if one wished to prepare 300 mL of a preserved HA composition according to the invention, one could dissolve HA or a pharmaceutically-acceptable salt thereof (such as sodium hyaluronate) in about 100 mL of solvent and dissolve BAK and/or another cationic preservative in about 200 mL of solvent. Once the HA and BAK are dissolved in their respective quantities of solvent, the solutions are combined to yield a BAK-preserved composition exhibiting little or no HA-BAK conjugation or precipitation.
- While the ratio of solvent quantities used to dissolve the BAK and HA is described above as about 2:1, this ratio is merely a preferred ratio. Effective compositions may be prepared with ratios between about 1.8:1 and 2.2:1.
- Compositions according to the invention may be prepared using any number of solvents, subject to their suitability for administration. For ophthalmic, nasal, and otic compositions, the solvent is typically aqueous, comprising water alone or in combination with one or more other solvents. Suitable solvents for ophthalmic, nasal, and otic compositions include, for example, glycerin, polyethylene glycol (PEG), and propylene glycol.
- Any species or combination of species of BAK may be used in practicing the invention. Generally defined, BAK has the formula: [C6H5CH2N(CH3)R]Cl, wherein R is an alkyl group having between eight and 18 carbon atoms.
- Where BAK is the cationic preservative used, compositions according to the invention optionally contain between about 0.001% and about 0.02% BAK or, optionally, between about 0.002% and about 0.01% BAK, or, optionally, between about 0.003% and about 0.005% BAK, or, optionally about 0.005% BAK. Such concentrations of BAK may be obtained by diluting commercially-available BAK solutions, which are available in any number of concentrations. Most commercially-available BAK solutions contain between about 5% and about 50% BAK. In certain embodiments, the BAK solutions contain between about 10% and about 30% BAK, or, optionally, between about 15% and about 19% BAK, or, optionally, about 17% BAK. A more detailed discussion of BAK can be found in U.S. Patent Publication 20060069162, herein incorporated by reference in its entirety.
- Similarly, any species or combination of species of HA may be used in practicing the invention. In certain embodiments, the HA has a molecular weight between about 500,000 daltons and about 4,000,000 daltons, or, optionally, between about 1,000,000 daltons and about 2,000,000 daltons, or, optionally, between about 1,200,000 daltons and about 1,800,000 daltons. Certain embodiments of the present invention contain between about 0.1% and about 0.5% HA, or, optionally, between about 0.2% and about 0.4% HA, or, optionally, about 0.2% HA. More detailed discussions of HA can be found in U.S. Patent Publication 20060094643; and U.S. Pat. Nos. 3,396,081; 3,862,003; 4,141,973; 4,517,296; 4,851,521; 4,965,353; 5,202,431; 5,316,926; 6,090,596; and 6,339,074, each of which patents are herein incorporated by reference in its entirety.
- Once the HA and BAK solutions are combined, the composition may optionally be filtered to remove any minor HA-BAK precipitants or other agents affecting the composition's clarity. In certain embodiments, the compositions of the invention has a transmittance between about 93% and about 98% at 440 nm before filtration and a transmittance between about 95% and about 100% at 440 nm after filtration. Any method of filtration suitable for use with pharmaceutical compositions may be employed in practicing the invention.
- Alternative cationic preservatives useful either alone or in combination with BAK include, but are not limited to, poly[dimethylimino-w-butene-1,4-diyl] chloride, alpha-[4-tris(2-hydroxyethyl)ammonium]-dichloride (Polyquaternium 1®), poly (oxyethyl (dimethyliminio)ethylene dmethyliminio) ethylene dichloride (WSCP®), benzalkonium halides other than BAK, salts of alexidine, alexidine-free base, salts of chlorhexidine, hexetidine, alkylamines, alkyl di- and tri-amine, Octenidine (N,N[prime]-(1,10-Decanediyldi-1-(4H)-pyridinyl-4-ylidenebis-[1-octanamine] dihydrochloride, cetylpyridinium chloride, cetylpyridinium salts, antimicrobial polypeptides, or mixtures thereof.
- Compositions according to the invention may contain additional components, such as those commonly found in ophthalmic, nasal, and otic compositions. Such additional components include, for example, cellulose derivatives, medicaments (e.g., antibacterials, antifungals, etc.), and buffers (e.g., phosphate buffers, borate buffers, citrate buffers, etc.). Other components may be included in compositions according to the invention, depending upon how and where the composition is to be administered. A more detailed discussion of such components can be found in US Patent Publication 2007036829, herein incorporated by reference in its entirety.
- A common class of additional components useful in ophthalmic, nasal, and otic compositions, is anionic cellulose derivatives. These may be defined as carboxyalkyl celluloses and hydroxyalkyl celluloses where the alkyl group includes between 1 and 3 carbon atoms. In certain embodiments, the anionic cellulose derivative is selected from the group consisting of, carboxymethylethylcellulose, ethyl carboxyethyl cellulose, carboxymethylhydroxyethylcelluloses, hydroxypropylmethylcelluloses, metal salts of carboxymethyl cellulose (such as sodium carboxymethyl cellulose) and mixtures thereof. In certain embodiments, the anionic cellulose derivative is a metal salt of carboxymethyl cellulose. Where used, one or more anionic cellulose derivatives may be dissolved in the fraction containing the cationic preservative, which is then combined with the fraction containing the HA or pharmaceutically-acceptable salt thereof. In certain embodiments, the anionic cellulose derivatives employed have molecular weight range of from about 70,000 daltons to about 700,000 daltons.
- Alternatively, a third fraction of solvent may be separately employed to dissolve the CMC, which is then combined with the dissolved HA, the dissolved cationic preservative, or the combined HA (or pharmaceutically-acceptable salt) and cationic preservative fractions. In such an embodiment, the solvent fractions are optionally in a ratio of about 1:1:1. For example, if one were to prepare 300 mL of a composition according to the invention, about 100 mL of solvent would be used to separately dissolve the HA (or pharmaceutically-acceptable salt), the cationic preservative, and the CMC.
- The preparation of compositions according to the invention will be described with reference to the following examples.
- 1. Dissolve a quantity of sodium hyaluronate in 100 mL of water to a concentration of 0.4%.
- 2. Dissolve a quantity of BAK in 200 mL of water to a concentration of 0.005%.
- 3. To the dissolved BAK, add and dissolve a quantity of CMC to a concentration of 0.5%.
- 4. Add the dissolved sodium hyaluronate solution to the dissolved BAK-CMC solution.
- The method of Example 1 yielded 300 mL of an aqueous composition comprising: 0.133% sodium hyaluronate, 0.0033% BAK, and 0.33% CMC.
- 1. Dissolve a quantity of sodium hyaluronate in 100 mL of water to a concentration of 0.6%.
- 2. Dissolve a quantity of CMC in 100 mL of water to a concentration of 1.5%.
- 3. Dissolve a quantity of BAK in 100 mL of water to a concentration of 0.015%.
- 4. Add the dissolved sodium hyaluronate solution to the dissolved BAK solution.
- 5. Add the dissolved CMC solution to the combined sodium hyaluronate-BAK solution.
- 6. Filter the combined sodium hyaluronate-BAK-CMC solution.
- The method of Example 2 yielded 300 mL of an aqueous composition comprising: 0.2% sodium hyaluronate, 0.005% BAK, and 0.5% CMC. The filtered solution had a transmittance of about 100%.
- The foregoing description of various aspects of the invention has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise form disclosed, and obviously, many modifications and variations are possible. Such modifications and variations that may be apparent to a person skilled in the art are intended to be included within the scope of the invention as defined by the accompanying claims.
Claims (20)
1. A method for preparing a preserved hyaluronic acid composition, the method comprising:
dissolving a cationic preservative in a first quantity of a solvent;
dissolving a quantity of hyaluronic acid (HA) or physiologically-acceptable salt thereof in a second quantity of the solvent; and
adding the dissolved HA or physiologically-acceptable salt thereof to the dissolved cationic preservative,
wherein precipitation of the cationic preservative and the HA or physiologically-acceptable salt thereof is substantially prevented by dissolving each in the first and second quantities of solvent before they are combined.
2. The method of claim 1 , wherein the cationic preservative includes benzalkonium chloride (BAK).
3. The method of claim 2 , wherein the BAK has the formula:
[C6H5CH2N(CH3)R]Cl, wherein R is an alkyl group having between eight and 18 carbon atoms.
4. The method of claim 2 , wherein the BAK is in solution form.
5. The method of claim 4 , wherein the solution includes BAK at a concentration between about 5% and about 50%.
6. The method of claim 5 , wherein the concentration of BAK is between about 10% and about 30%.
7. The method of claim 1 , wherein the physiologically-acceptable salt includes sodium hyaluronate.
8. The method of claim 1 , wherein the HA has a molecular weight between about 500,000 daltons and about 4,000,000 daltons.
9. The method of claim 8 , wherein the molecular weight is between about 1,000,000 daltons and about 2,000,000 daltons.
10. The method of claim 1 , wherein the solvent includes water.
11. The method of claim 10 , wherein the solvent further includes at least one of the following: glycerin, polyethylene glycol (PEG), and propylene glycol.
12. The method of claim 1 , wherein a ratio of the first quantity of the solvent to the second quantity of the solvent is between about 1.8:1 and about 2.2:1.
13. The method of claim 12 , wherein the ratio is about 2:1.
14. The method of claim 1 , further comprising:
filtering the combined HA or physiologically-acceptable salt thereof and cationic preservative solution.
15. The method of claim 14 , wherein the HA or physiologically-acceptable salt thereof and cationic preservative solution has a transmittance between about 93% and about 98% at 440 nm before filtration.
16. The method of claim 14 , wherein the combined HA or physiologically-acceptable salt thereof and cationic preservative solution has a transmittance between about 95% and about 100% at 440 nm after filtration.
17. The method of claim 1 , wherein the composition has a concentration of unprecipitated HA between about 0.1% and about 0.5%.
18. A composition prepared according to the method of claim 1 .
19. A method for preparing a preserved hyaluronic acid composition, the method comprising:
dissolving a cationic preservative in a first quantity of a solvent;
dissolving a quantity of hyaluronic acid (HA) or physiologically-acceptable salt thereof in a second quantity of the solvent;
dissolving a quantity of an anionic cellulose derivative in a third quantity of the solvent;
adding the dissolved HA or physiologically-acceptable salt thereof to the dissolved cationic preservative; and
adding the dissolved anionic cellulose derivative to at least one of the following: the dissolved HA or physiologically-acceptable salt thereof, the dissolved cationic preservative, and the combined dissolved HA or physiologically-acceptable salt thereof and cationic preservative,
wherein precipitation of the cationic preservative and the HA or physiologically-acceptable salt thereof is substantially prevented by dissolving each in the first and second quantities of solvent before they are combined.
20. A preserved aqueous composition comprising:
a solvent;
hyaluronic acid (HA) or a physiologically-acceptable salt thereof; and
an effective amount of a cationic preservative including benzalkonium chloride (BAK) having the formula [C6H5CH2N(CH3)R]Cl, wherein R is an alkyl group having at least one of: between eight and 10 and between 14 and 18 carbon atoms,
wherein the composition is substantially free of precipitants of the cationic preservative and the HA or physiologically-acceptable salt thereof.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/408,748 US20170119888A1 (en) | 2007-05-16 | 2017-01-18 | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
US16/186,866 US10588977B2 (en) | 2007-05-16 | 2018-11-12 | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
US16/780,073 US20200171158A1 (en) | 2007-05-16 | 2020-02-03 | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/803,873 US8609634B2 (en) | 2007-05-16 | 2007-05-16 | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
US14/086,548 US9579341B2 (en) | 2007-05-16 | 2013-11-21 | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
US15/408,748 US20170119888A1 (en) | 2007-05-16 | 2017-01-18 | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/086,548 Continuation US9579341B2 (en) | 2007-05-16 | 2013-11-21 | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/186,866 Continuation US10588977B2 (en) | 2007-05-16 | 2018-11-12 | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170119888A1 true US20170119888A1 (en) | 2017-05-04 |
Family
ID=53173915
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/086,548 Active 2027-08-29 US9579341B2 (en) | 2007-05-16 | 2013-11-21 | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
US15/408,748 Abandoned US20170119888A1 (en) | 2007-05-16 | 2017-01-18 | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
US16/186,866 Active US10588977B2 (en) | 2007-05-16 | 2018-11-12 | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
US16/780,073 Abandoned US20200171158A1 (en) | 2007-05-16 | 2020-02-03 | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/086,548 Active 2027-08-29 US9579341B2 (en) | 2007-05-16 | 2013-11-21 | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/186,866 Active US10588977B2 (en) | 2007-05-16 | 2018-11-12 | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
US16/780,073 Abandoned US20200171158A1 (en) | 2007-05-16 | 2020-02-03 | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
Country Status (1)
Country | Link |
---|---|
US (4) | US9579341B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9579341B2 (en) | 2007-05-16 | 2017-02-28 | Johnson & Johnson Consumer Inc. | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT252264B (en) | 1965-03-17 | 1967-02-10 | Etapharm Chem Pharm Lab Ges M | Process for the production of a pure, highly viscous hyaluronic acid preparation |
JPS5318520B2 (en) | 1972-07-05 | 1978-06-15 | ||
AU499860B2 (en) | 1975-04-24 | 1979-05-03 | Honda Giken Kogyo Kabushiki Kaisha | Deflector plate to equalise fuel distribution in induction gas flow |
US4141973A (en) | 1975-10-17 | 1979-02-27 | Biotrics, Inc. | Ultrapure hyaluronic acid and the use thereof |
US4371522A (en) | 1979-04-25 | 1983-02-01 | Gilbard Jeffrey P | Keratoconjunctivitis sicca therapy |
US4443432A (en) | 1981-10-05 | 1984-04-17 | Alcon Laboratories, Inc. | Ophthmalic irrigating solution |
JPS5945890A (en) | 1982-09-09 | 1984-03-14 | Toyo Jozo Co Ltd | Novel antibiotic acmimycin and its preparation |
US5316926A (en) | 1983-11-25 | 1994-05-31 | Miles Inc. | Method for the microbiological production of non-antigenic hyaluronic acid |
US5409904A (en) | 1984-11-13 | 1995-04-25 | Alcon Laboratories, Inc. | Hyaluronic acid compositions and methods |
US5202431A (en) | 1985-07-08 | 1993-04-13 | Fidia, S.P.A. | Partial esters of hyaluronic acid |
US4851521A (en) | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
US4711249A (en) | 1986-07-23 | 1987-12-08 | Brooks Albert E | Circumferential membrane, fluid coupled catheter |
JPH075456B2 (en) | 1988-10-01 | 1995-01-25 | 参天製薬株式会社 | Eye drops |
JP2788502B2 (en) | 1989-08-18 | 1998-08-20 | 株式会社日本触媒 | Magnetic recording media |
DE69116010T2 (en) | 1990-06-29 | 1996-05-30 | Santen Pharmaceutical Co Ltd | Use of a composition for the manufacture of a medicament for removing the residues of lens materials |
JP3050898B2 (en) | 1990-07-06 | 2000-06-12 | 千寿製薬株式会社 | Aqueous pharmaceutical preparation |
US5492936A (en) | 1990-11-30 | 1996-02-20 | Allergan, Inc. | Bimodal molecular weight hyaluronate formulations and methods for using same |
US5505953A (en) | 1992-05-06 | 1996-04-09 | Alcon Laboratories, Inc. | Use of borate-polyol complexes in ophthalmic compositions |
WO1993021903A1 (en) | 1992-05-06 | 1993-11-11 | Alcon Laboratories, Inc. | Use of borate-polyol complexes in ophthalmic compositions |
ITPD940054A1 (en) | 1994-03-23 | 1995-09-23 | Fidia Advanced Biopolymers Srl | SULPHATED POLYSACCHARIDES |
JP2935339B2 (en) | 1994-04-28 | 1999-08-16 | 日本化薬株式会社 | External disinfectant |
SE9401806D0 (en) | 1994-05-26 | 1994-05-26 | Pharmacia Ab | Method and means for the production of hyaluronic acid |
IT1273011B (en) | 1994-07-25 | 1997-07-01 | Trhecnopharma S A | OPHTHALMIC PREPARATION FOR USE AS ARTIFICIAL LACRIMA |
JPH09176020A (en) | 1995-12-28 | 1997-07-08 | Takada Seiyaku Kk | Stable solution containing sodium hyaluronate |
JPH1160505A (en) | 1997-05-20 | 1999-03-02 | Senju Pharmaceut Co Ltd | Antiseptic composition |
JP3050898U (en) | 1998-01-26 | 1998-08-07 | 文龍 葉 | Cooling device for circulating chilled water in air conditioners |
US7691829B2 (en) | 1998-03-24 | 2010-04-06 | Petito George D | Composition and method for healing tissues |
KR100354606B1 (en) | 2000-02-01 | 2002-09-30 | 주식회사 중외제약 | Composition of multi-purpose solution for treating contact lens |
JP2002020279A (en) | 2000-06-30 | 2002-01-23 | Taisho Pharmaceut Co Ltd | Eye lotion |
JP2002356420A (en) | 2001-03-27 | 2002-12-13 | Santen Pharmaceut Co Ltd | Table aqueous liquid medicine |
GB2376956B (en) * | 2002-06-12 | 2003-05-14 | Philip Shad | Sewing machine having a wireless switch and independant controller |
CN1671400A (en) | 2002-07-03 | 2005-09-21 | 派瑞克科学公司 | Compositions of hyaluronic acid and methods of use |
KR20050057251A (en) | 2002-09-09 | 2005-06-16 | 산텐 세이야꾸 가부시키가이샤 | Transparent eye drops containing latanoprost |
US20050196370A1 (en) * | 2003-03-18 | 2005-09-08 | Zhi-Jian Yu | Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye |
JP3876232B2 (en) | 2003-04-18 | 2007-01-31 | 有限会社ユーワ商事 | Ophthalmic preparations, eye drops, artificial tears, contact lens care products, eye washes, and eye ointments |
SI1759702T1 (en) * | 2004-05-26 | 2009-06-30 | Bayardo Arturo Jimenez | Method of preparing a latanoprost ophthalmic solution and solution thus produced |
EP1809242B1 (en) * | 2004-11-09 | 2013-03-20 | Abbott Medical Optics Inc. | Contact lens disinfection and packaging solution |
US8609634B2 (en) | 2007-05-16 | 2013-12-17 | Mcneil-Ppc, Inc. | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
US9579341B2 (en) | 2007-05-16 | 2017-02-28 | Johnson & Johnson Consumer Inc. | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
US20100234319A1 (en) * | 2009-03-11 | 2010-09-16 | Abbott Medical Optics Inc. | Complex of Polymeric Quaternary Ammonium and Anionic Polymers as a New Antimicrobial Agent for Ophthalmic Compositions |
US8306873B2 (en) | 2009-11-11 | 2012-11-06 | Joe Smith | System and method of media distribution management |
-
2013
- 2013-11-21 US US14/086,548 patent/US9579341B2/en active Active
-
2017
- 2017-01-18 US US15/408,748 patent/US20170119888A1/en not_active Abandoned
-
2018
- 2018-11-12 US US16/186,866 patent/US10588977B2/en active Active
-
2020
- 2020-02-03 US US16/780,073 patent/US20200171158A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US9579341B2 (en) | 2017-02-28 |
US20150141368A1 (en) | 2015-05-21 |
US20200171158A1 (en) | 2020-06-04 |
US20190076534A1 (en) | 2019-03-14 |
US10588977B2 (en) | 2020-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8609634B2 (en) | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods | |
KR101821518B1 (en) | High concentration olopatadine ophthalmic composition | |
US20090209599A1 (en) | Eye drop containing roflumilast | |
JP2017190348A (en) | Aqueous ophthalmic composition | |
US10588977B2 (en) | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods | |
JP3659801B2 (en) | Tranilast aqueous solution formulation | |
KR20130100273A (en) | Aqueous composition for ophthalmic administration | |
JP4757970B2 (en) | Eye drop composition | |
JP2002316926A (en) | Ophthalmic composition for contact lens and method for mitigating ocular irritation | |
JP3876232B2 (en) | Ophthalmic preparations, eye drops, artificial tears, contact lens care products, eye washes, and eye ointments | |
AU2022200370A1 (en) | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods | |
AU2019275608A1 (en) | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods | |
JP5906294B2 (en) | Eye drops | |
JPH085779B2 (en) | Fleroxacin eye drops | |
AU2013206362A1 (en) | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods | |
JP4294276B2 (en) | Eye drop composition | |
KR20210158355A (en) | Ophthalmic Composition Comprising Diquafosol | |
JP2005008625A (en) | Eye lotion containing quinolone-based antibacterial compound | |
JPS5989616A (en) | Eye drop | |
JP6077860B2 (en) | Liquid | |
JP2008088192A (en) | Eye lotion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |